News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS ANNOUNCES INTENTION TO FLOAT ON THE SIX SWISS EXCHANGE
BioVersys AG announces intention to float on SIX Swiss Exchange, targeting primary-only proceeds of approx. CHF 80 million to advance lead asset BV100 through Phase 3 and finance operating expenses. IPO supported by AMR Action Fund and GSK -
-
COMMUNIQUÉ DE PRESSE
Kontron expects further revenue growth and a disproportionately high increase in operating earnings in 2025
Kontron anticipates revenue growth and significant increase in operating earnings for 2025, with preliminary 2024 results exceeding expectations. Strong momentum expected from IoT innovations -
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis et AskHelpU signent un accord de co-développement dans les maladies rares neuromusculaires en Chine
Biophy's et AskHelpU signent un accord de co-développement dans les maladies rares neuromusculaires en Chine. Analyse de l'efficacité du candidat-médicament BIO101 de Biophytis dans la SLA -
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Biophy's and AskHelpU sign a co-development agreement for rare neuromuscular diseases in China. The agreement aims to evaluate BIO101's efficacy in ALS, potentially offering a major therapeutic solution for patients -
-
